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B. pertussis outer membrane vesicles (OMV) contain ACT on their surface (OMV–ACT), but the
properties of OMV–ACT were previously unknown. We found that B. pertussis in the lung from a
fatal pertussis case contains OMV, suggesting an involvement in pathogenesis. OMV–ACT and ACT
intoxicate cells with and without the toxin’s receptor CD11b/CD18. Intoxication by ACT is blocked
by antitoxin and anti-CD11b antibodies, but not by cytochalasin-D; in contrast, OMV–ACT is unaf-
fected by either antibody and blocked by cytochalasin-D. Thus OMV–ACT can deliver ACT by pro-
cesses distinct from those of ACT alone.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bordetella pertussis is the causative agent of whooping cough,
which is increasing in incidence, despite high immunization rates
[1]. This Gram-negative organism produces a number of virulence
factors, including adenylate cyclase toxin (ACT), ﬁlamentous hem-
agglutinin (FHA), pertactin (PRN) and pertussis toxin (PT) [2]. ACT
uses the aMb2 integrin CD11b/CD18 as a receptor, but also intoxi-
cates cells not expressing CD11b/CD18 [3–5]. Following binding,
regardless of CD11b/CD18, the ACT catalytic domain is translo-
cated into the cell and activated by calmodulin to convert ATP to
cyclic AMP (cAMP), a process referred to in this study and
elsewhere as ‘‘intoxication’’.
Most Gram-negative bacteria produce outer membrane vesicles
(OMV) containing outer-membrane proteins, carbohydrates and
lipids. These structures have been extensively studied and recog-
nized to have a role in pathogenesis of some bacterial infectious
diseases [6,7]. Hozbor et al. showed that B. pertussis produce
OMV containing ACT (OMV–ACT) and other virulence factors and
proposed use of these OMV as an acellular pertussis vaccine
[8,9]. Virtually nothing is known about the effects of OMV–ACT,
as illustrated by the fact that neither the Hozbor publications norchemical Societies. Published by E
5 Crispell Dr, Box 800419,
Fax: +1 434 982 3830.
).two recent reviews on OMV contain information on virulence-
associated activities of OMV–ACT. In our studies of intoxication
by OMV–ACT, we ﬁnd that OMV–ACT acts as a delivery system
for ACT, but by a process that is different from that used by puriﬁed
ACT.
2. Materials and methods
2.1. B. pertussis growth
B. pertussis strains (GMT1, GMT1(pTH22) and BP348) were
grown on Bordet–Gengou (BG) agar (Difco) containing 10% deﬁ-
brinated sheep blood (Cocalico) and then modiﬁed Stainer–Scholte
liquid medium (SSM) [10] at 35.5 C. GMT1 is a wild-type B. pertus-
sis strain [11] and BP348 contains a transposon insertion in cyaA
[12], rendering it defective in the production of ACT. GMT1(pTH22)
was created for this study, as described below.
2.2. Isolation of outer membrane vesicles (OMV)
OMV were isolated from culture supernatants and bacterial
cells as described by Hozbor et al. [8]. For OMV from culture super-
natant (referred to as ‘‘native OMV’’), GMT1 was grown in SSM,
centrifuged and ﬁltered to remove remaining bacteria. OMV were
obtained by centrifugation at 150000g for 1 h at 4 C and wash-lsevier B.V. All rights reserved.
Fig. 1. B. pertussis organisms and OMV in human pathology specimens. Electron microscopic images of outer membrane vesicles associated with B. pertussis are from lung
tissue obtained at autopsy from a child with fatal B. pertussis infection. Arrows indicate OMV. Scale bar = 0.1 lm; magniﬁcation = 30000.
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centrifugation, OMV pellets were stored in TE at 20 C.
For OMV from treatment of bacteria (designated ‘‘enriched
OMV’’), strains were grown to logarithmic phase, centrifuged and
resuspended in TE. OMV were released by sonication on ice in ﬁve,
1-min bursts. The bacteria were removed by centrifugation and the
OMV-containing supernatants were centrifuged at 100000g for
2 h at 4 C. The pellets were resuspended in 2% deoxycholate
(DOC) and further puriﬁed by centrifugation on a 60% sucrose
cushion at 100000g for 2 h at 4 C. The OMV band was collectedFig. 2. Transmission EM images of B. pertussis and OMV. (A) B. pertussis GMT1 and associ
to the bacterial surface; bracket represents OMV released into the culture medium; scale
attached OMV stained with uranyl acetate and lead citrate. Scale bar = 0.2 lm; magniﬁca
et al. [8] were negatively stained with 2% PTA pH 7.0. Scale bar = 0.5 lm; magniﬁcation =
from GMT1. The comparison of intoxication was based on equalized AC enzymatic activi
⁄P < 0.0001 compared to GMT1 enriched OMV.from the interface, washed and stored in TE at20 C. OMV protein
concentrations were determined by BCA protein assay (Pierce). The
absence of viable bacteria in the OMV was established by lack of
growth on BG plates.
2.3. Electron microscopy
For B. pertussis cultured in vitro, an aliquot of GMT1 or isolated
OMV was added to formvar and carbon-coated, nickel-mesh grids
for 1 min, excess liquid removed and samples negatively stainedated OMV were negatively stained with 2% NanoVan. Arrows indicate OMV attached
bar = 1 lm; magniﬁcation = 15000. (B) Ultrathin section of embedded bacteria and
tion = 40000. (C) OMV prepared and puriﬁed from GMT1 by the method of Hozbor
30000. (D) J774.A1 cells were intoxicated comparably by enriched and native OMV
ties. Enriched OMV from the ACT-negative strain, BP348, did not cause intoxication.
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(PTA) pH 7.0 for 1 min. Bacteria and vesicles were visualized by
TEM. For high resolution images, GMT1 was prepared for section-
ing by ﬁxing in 2.5% glutaraldehyde for 1 h at room temperature
(RT). Bacteria were centrifuged, washed in 0.1 M phosphate buffer
pH 7.4, post-ﬁxed for 1 h in 1% osmium tetroxide, dehydrated and
embedded in epoxy resin (EMBED 812; Electron Microscopy
Sciences). After polymerization, ultrathin sections were collected,
mounted, stained with uranyl acetate and lead citrate and exam-
ined according to routine procedures.
For autopsy samples, formalin-ﬁxed, parafﬁn-embedded lung
tissue was deparafﬁnized, post-ﬁxed in 1% osmium tetroxide,
dehydrated, and embedded in a mixture of Epon substitute and
Araldite. Sections were stained with uranyl acetate and lead citrate
and microscopy was performed at the CDC, as previously described
[13].
2.4. Adenylate cyclase enzymatic activity and preparation of puriﬁed
ACT
AC enzymatic activity was measured by the conversion of [32P]-
ATP to [32P]-cAMP, as previously described [14]. Comparisons
between native and enriched OMV and between OMV–ACT and
puriﬁed ACT were made on the basis of equalized AC enzymatic
activities.
ACT was expressed from Escherichia coli XL-1 Blue and puriﬁed
by ion exchange and afﬁnity chromatographies, as described previ-
ously [15].Fig. 3. Distribution of periplasmic and cytoplasmic markers in B. pertussis and OMV. (A)
was fractionated and the periplasmic and cytoplasmic fractions assayed for AP activity
Enriched OMV from GMT1(pTH22) were lysed and assayed for AP enzyme activity. AP ac
fraction. Representative graph from 3 independent experiments. (C) Enriched GMT1 OMV
a decrease in OD340. MDH activity of the B. pertussis lysate is shown in inset. Representa2.5. Intoxication
J774A.1 cells (murine macrophage cell line) and CHO-K1 cells
(Chinese hamster ovary epithelial cell line) were grown in 96-well
plates in Dulbecco’s modiﬁed Eagle’s medium with high glucose
(DMEM; Gibco) or Ham’s F12 medium with L-glutamine (Gibco),
respectively, plus 10% heat-inactivated fetal bovine serum (FBS;
Gibco). Puriﬁed ACT or OMV–ACT was added to cells, which were
then incubated 1 h, washed twice and lysed for cAMP measure-
ment using a chemiluminescence-based ELISA (cAMP-screen
system; Applied Biosystems).
2.6. Characterization of OMV contents
We introduced E. coli phoA (encoding alkaline phosphatase) into
B. pertussis speciﬁcally for the purpose of validating enriched OMV.
Since OMV arise by budding from the outer membrane indepen-
dent of the cytoplasmic membrane and cytosol, they are expected
to contain periplasmic proteins and to exclude cytosolic proteins.
GMT1 was conjugated with an E. coli donor strain SM10(pTH22)
(kindly provided by Drusilla Burns, FDA), which carries phoA
[16]. Ex-conjugates were selected on BG agar containing gentami-
cin and streptomycin. The resulting strain, which was designated
GMT1(pTH22), was grown in SSM and fractionated to yield peri-
plasmic and cytoplasmic compartments, as previously described
[17]. The bacterial pellet was resuspended in 0.2 M Tris pH 8.0
and spheroplast buffer (0.2 M Tris pH 8.0, 1 M sucrose, 0.5% Zwit-
tergent-316, 0.1 mg/ml lysozyme) was added. The supernatant
following centrifugation contained the periplasmic fraction andGMT1(pTH22), a B. pertussis strain expressing the periplasmic enzyme marker, AP,
. Data represent the blanked mean ± S.E.M. from 4 independent experiments. (B)
tivity was detected in the OMV lysate and luminal fraction, but not the membrane
were lysed and assayed for MDH via the oxidation of b-NADH, which is reﬂected as
tive graph from 3 independent experiments.
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fraction.
Enriched OMV (20 lg) from GMT1- and GMT1(pTH22) were
lysed by rotating at RT for 2 h in spheroplast buffer (described
above) to obtain total lysate. After an aliquot was removed, the
remainder was centrifuged at 144000g for 1 h at 4 C to obtain
lumen and membrane fractions. The membranes were resus-
pended in TE and both fractions stored at 20 C. Alkaline phos-
phatase (AP) activity was measured according to the method
described by Brickman and Beckwith, with minor modiﬁcations
[18]. E. coli AP (MP Biomedicals) was the positive control. The assay
for malate dehydrogenase (MDH) was performed as suggested by
the manufacturer of the substrates and enzyme (Sigma). Porcine
heart MDH (Sigma) was used as a positive control. Incubation of
B. pertussis on ice for 10 min in a lysis buffer, followed by freeze–
thaw cycles and sonication, yielded a bacterial whole cell lysate
as a control.
2.7. Trypsin sensitivity
OMV–ACT and puriﬁed ACT were treated with trypsin (40 lg/
ml, 5 min, 37 C) and then 80 lg/ml trypsin inhibitor was added
to stop the reaction. As controls, OMV–ACT and puriﬁed ACT were
treated with trypsin inhibitor prior to the addition of trypsin, in
order to mimic the experimental conditions. Enzyme activity and
intoxication were measured, as described above.
2.8. Antibody and cytochalasin-D treatments
OMV–ACT and puriﬁed ACT were incubated (10 min, 4 C) with
20 lg/ml 3D1 or control mouse IgG antibody (Sigma) and then
added to macrophages. Alternatively, macrophages were treated
(1 h, 4 C) with 10 lg/ml anti-CD11b (M1/70) or control rat IgG2b
antibody (BD Pharmingen) before ACT or OMV–ACT was added.
Intoxication was measured after 1 h, as described above. Intoxica-
tion in the absence of prior incubation with either antibody served
as control.
J774A.1 and CHO cells were incubated with or without 10 lg/ml
cytochalasin-D, then OMV–ACT or puriﬁed ACT was added to the
cells, incubated an additional 1 h at 37 C and cAMP was measured.
As controls, cytochalasin-D (10 lg/ml) and DMSO (ﬁnal concentra-
tion of 1%) were added separately to target cells and cAMP
quantiﬁed.Fig. 4. Trypsin-sensitivity assay. OMV–ACT and puriﬁed ACT were incubated with
or without 40 lg/ml trypsin for 5 min at 37 C and then, 80 lg/ml trypsin inhibitor
was added. As a control, samples were incubated with trypsin inhibitor prior to
trypsin treatment. These samples were assayed for (A) adenylate cyclase enzymatic
activity and (B) intoxication. Data reported as a percentage of the untreated
controls, which were set at 100%. At equivalent ACT enzymatic activity, intoxication
for puriﬁed ACT was 9215 ± 1241 pmol cAMP/mg J774A.1 protein and for OMV–ACT
it was 9896 ± 270 pmol cAMP/mg J774A.1 protein. All data represent the mean ± -
S.E.M. with background subtracted of duplicate samples from at least 2 indepen-
dent experiments. ⁄P < 0.007 compared to untreated controls.3. Results and discussion
In light of the observations of Hozbor et al. [8], we asked
whether OMV are produced in vivo during infection with B. pertus-
sis. Previously, autopsy airway specimens from children, who died
of pertussis, were examined using electron microscopy [13]. B. per-
tussis organisms were identiﬁed in the cilia of respiratory epithe-
lium of a subsegemental bronchus in a section of lung tissue by
immunohistochemical staining and molecular analysis [13], as
well as by using immunoelectron microscopy (data not shown).
As shown in Fig. 1, these lung sections from a fatal case of pertussis
reveal B. pertussis organisms with associated OMV, some in the
process of forming and others already released. These images,
which illustrate for the ﬁrst time B. pertussis OMV in vivo,
prompted investigation of a possible role for OMV in the delivery
of ACT to host cells.
This investigation began with characterization of B. pertussis
OMV and optimization of their preparation. Transmission electron
microscopy (TEM) of negatively stained, unﬁxed B. pertussis
(GMT1) from an overnight culture reveals vesicles attached to the
cell surface and released into the medium (Fig. 2A). Stained, ultra-thin sections of ﬁxed and embedded bacteria allow a higher resolu-
tion image of the native OMV, with characteristic membrane
bilayer surrounding electron-dense material (Fig. 2B). B. pertussis
native OMV (Fig. 2A) and enriched OMV (Fig. 2C) exhibit similar
morphologies. Importantly, as shown in Fig. 2D, native OMV and
enriched OMV at equal amounts of enzymatic activity are compara-
ble in their ability to elicit cAMP production in J774.A1 cells. En-
riched OMV from ACT-negative strain, BP348, serve as the
negative control.
By virtue of the process by which OMV are formed, budding of
outer membrane without disturbing the cytoplasmic membrane,
they contain periplasmic components, but not material from the
cytoplasm [19–21]. To further validate the procedure used by Hoz-
bor et al., we characterized the luminal contents of enriched OMV.
A B. pertussis strain (GMT1(pTH22)) expressing E. coli alkaline
phosphatase (AP) was created speciﬁcally for this purpose, since
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94% of the AP activity from GMT1(pTH22) is periplasmic. In en-
riched OMV obtained from GMT1(pTH22), the AP activity was de-
tected solely in the OMV lumen fraction (Fig. 3B). We also tested
OMV from GMT1 for cytoplasmic contamination by assaying for
the intracellular enzyme malate dehydrogenase (MDH). Oxidation
of b-NADH by MDH results in a decrease in absorbance at 340 nm.
As shown in Fig. 3C, there is MDH activity from the
B. pertussiswhole cell lysate (inset panel) as well as the control en-
zyme from porcine heart, but none in OMV lysates or fractions
thereof.
Together, these data demonstrate that enriched OMV from B.
pertussis are comparable morphologically to native OMV and show
the characteristic features of OMV, namely containing periplasmic
AP, but no cytoplasmic MDH. Because the yield of native OMV pro-
duced by B. pertussis grown in vitro decreases by the ﬁltration step
necessary to remove residual bacteria from the culture medium,Fig. 5. Effect of antibodies and cytochalasin-D on intoxication by ACT and OMV–ACT. (A)
antibody (mouse isotype IgG1) for 10 min at 4 C and then added directly to J774A.1 cells
control antibody (rat isotype IgG2b) at 4 C for 1 h before puriﬁed ACT or OMV–ACT was a
as a percentage of the untreated controls, which were set at 100%. At equivalent ACT e
protein and for OMV–ACT it was 5117 ± 442 pmol cAMP/mg J774A.1 protein. All data rep
least 2 independent experiments. ⁄P < 0.0018 compared to untreated controls. (B) J774.A
37 C before OMV–ACT or puriﬁed ACT was added and incubated an additional hour at 37
treated with cytochalasin-D as described in (B), equal amounts of OMV–ACT were added
mg cell protein; DMSO-treated control cells was 37 ± 6 pmol cAMP/mg cell protein. All
experiments. ⁄P < 0.0045 compared to untreated controls.and the comparability of native and enriched OMV, we used en-
riched OMV for the subsequent studies of OMV–ACT.
It was recognized at the time of discovery of B. pertussis ACT
that a large amount of toxin is associated with the bacterial surface
and both cell-associated and puriﬁed ACT are very sensitive to
trypsin [22]. Since OMV are derived from the outer membrane of
proliferating B. pertussis, we hypothesized that OMV–ACT would
be exposed on the external surface and thus susceptible to added
trypsin. As shown in Fig. 4A, exposure of OMV–ACT to trypsin re-
sults in an 88% decrease in AC enzymatic activity (as compared
to untreated OMV–ACT) and this loss of activity is accompanied
by an equivalent (91%) reduction in their ability to intoxicate
J774.A1 cells (Fig. 4B). When puriﬁed ACT is treated with trypsin
under the same conditions, there is a comparable loss of toxin
activity. Together, these data conﬁrm that OMV–ACT is in a loca-
tion, most likely the external surface of the OMV that makes it sus-
ceptible to exogenously added trypsin.OMV–ACT and puriﬁed ACT were incubated with 20 lg/ml anti-ACT (3D1) or control
. Alternatively, J774A.1 macrophages were pre-treated with 10 lg/ml anti-CD11b or
dded. Cells were incubated at 37 C for 1 h and then cAMP measured. Data reported
nzymatic activity, intoxication for ACT was 10280 ± 1786 pmol cAMP/mg J774A.1
resent the mean ± S.E.M. with background subtracted of duplicate samples from at
1 macrophages were incubated with or without 10 lg/ml cytochalasin-D for 1 h at
C. ⁄P = 0.0009 compared to untreated control. (C) J774.A1 and CHO cells were each
and incubated an additional hour at 37 C. Buffer control was 121 ± 23 pmol cAMP/
data represent the mean ± S.E.M. of duplicate samples from at least 2 independent
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hypothesized that this ACT could be transferred to target cells,
resulting in intoxication. This hypothesis, however, was not cor-
rect; it is newly secreted ACT that is responsible for intoxicating
cells [23]. In order to determine the relative proportion of ACT re-
leased as OMV-associated rather than free toxin, we isolated OMV
from culture supernatants and measured AC enzymatic activity.
We found that native OMV–ACT represents 1.2 ± 0.06% of the total
ACT released into the bacteria-cleared supernatant of B. pertussis
cultures grown in vitro. Our discovery that OMV–ACT is able to de-
liver ACT and thus intoxicate target cells provides a potential alter-
native mechanism by which ACT on the bacterial surface may
contribute to intoxication of host cells. To understand this process
better, we investigated the mechanism by which eukaryotic cells
are intoxicated by OMV–ACT.
Intoxication by puriﬁed ACT involves binding to CD11b/CD18,
when present, and translocation into the cell. This intoxication is
inhibited >95% by preventing binding of ACT to its receptor with
anti-CD11b antibody or by interfering with translocation with
anti-ACT monoclonal antibody 3D1 [3,24]. As expected, intoxica-
tion by puriﬁed ACT is reduced >96% (compared to the untreated
cells) by either antibody, but unaffected by isotype controls
(Fig. 5A). In contrast, intoxication of J774.A1 cells by OMV–ACT is
unaffected by either antibody.
Unlike other bacterial toxins whose entry into cells is mediated
by a toxin–receptor interaction and a host cell-mediated process,
the pathway by which isolated ACT enters host cells is not a
microﬁlament-dependent process, such as endocytosis or phago-
cytosis [25]. The differences between OMV–ACT and isolated ACT
in response to anti-toxin and anti-receptor antibodies suggest that
they enter by different mechanisms. To explore this hypothesis,
we evaluated the effects of cytochalasin-D, an inhibitor of micro-
ﬁlament function, on intoxication by OMV–ACT. Consistent with
previous ﬁndings, intoxication by ACT is not affected by cytocha-
lasin-D (Fig. 5B). In striking contrast, intoxication by OMV–ACT
is prevented by treatment with cytochalasin-D. To test whether
this response to OMV–ACT in J774.A1 cells is a general phenome-
non, we compared ACT and OMV–ACT in non-phagocytic, CD11b/
CD18-negative CHO cells. The potency of OMV–ACT is comparable
between cell types and the addition of cytochalasin-D to CHO cells
decreases OMV-mediated intoxication by 85% relative to untreated
cells (Fig. 5C). Overall these data suggest that the process by which
OMV–ACT intoxicates both cell types is CD11b/CD18-independent,
microﬁlament-dependent and mechanistically distinct from intox-
ication by isolated ACT. Thus, although OMV–ACT is unlikely the
primary pathway for ACT delivery since approximately only 1%
of the total released active ACT is secreted via native OMV, it
may provide an important supplemental mechanism for B. pertus-
sis intoxication of host cells. Since OMV-mediated delivery of ACT
could presumably occur at a distance and in the absence of bacte-
ria, OMV–ACT would circumvent the need for B. pertussis to be in
close contact with the host cell in order to exert its effects, as is
the requirement for newly synthesized ACT.
These results are particularly of interest in light of the recent
observations by Chatterjee and Chaudhuri on OMV from Vibrio
cholerae [26]. In studies of the delivery of cholera toxin (CT) to
intestinal epithelial cells by OMV, they observed that intoxication
is blocked by addition of the CT receptor, GM1 ganglioside, prior
to incubation with target cells. These data are interpreted to indi-
cate that the interaction of OMV-CT with the epithelial cells is
mediated by an interaction of CT with GM1. Similarly, E. coli heat-
labile toxin (LT) acts as an OMV adhesin, binding GM1 as does CT,
and leads to endocytosis [27]. VacA-containing vesicles are also
endocytosed into vacuoles as is soluble VacA, suggesting that the
recognition and processing may be the same [28]. In contrast, Acti-
nobacillus actinomycetemcomitans OMV, like those of B. pertussis,interact with target-cell membranes independent of the OMV-
associated leukotoxin or microﬁlament function [29]. Thus, there
are several mechanisms by which OMV deliver virulence factors
to host cells. Our studies establish that OMV from B. pertussis can
deliver ACT to target cells and that production of OMV occurs
in vivo during clinical pertussis.Acknowledgements
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